Find your next paid study

Avenzo Therapeutics, Inc.NCT07193511

Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumor…

PheochromocytomaParagangliomaNeuroendocrine Tumors+1 more

National Cancer Institute (NCI)NCT03206060

~$10 – $5,625

Advanced Solid TumorAdvanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as wel…

Vaxiion TherapeuticsNCT05901285

Observational

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton th…

Pediatric Solid TumorsRhabdomyosarcomaEwing Sarcoma+4 more

St. Jude Children's Research HospitalNCT07514819

~$10 – $6,250

Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recu…

Crossbow Therapeutics, Inc.NCT07779798

Ovarian CancerBreast CancerEndometrial Cancer+3 more

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and …

NextCure, Inc.NCT06774963

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Solid Tumors

Zai Lab (Shanghai) Co., Ltd.NCT06885281

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary …

Advanced Solid Tumors

CStone PharmaceuticalsNCT06741644

Healthy VolunteersRecurrent GliomaBrain Metastases From Extra-cranial Solid Tumors

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl…

University of Alabama at BirminghamNCT05676489

~$10 – $6,250

RET-altered Non Small Cell Lung CancerRET-altered Solid Tumors

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Pha…

Taiho Pharmaceutical Co., Ltd.NCT04683250

Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, ph…

Advanced Squamous Tumors

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy

Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPG…